Christoph Eimer

Summary

Affiliation: Kopf- und Halschirurgie
Country: Germany

Publications

  1. doi mTOR inhibition in advanced renal cell carcinoma: which criteria should be used to evaluate therapeutic outcome?
    Christoph Eimer
    Department of Urology, Lukas Hospital, Preussen Strasse 84, Neuss, Germany
    Anticancer Drugs 22:18-23. 2011
  2. doi Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy
    Holger Gerullis
    Department of Urology, Lukas Hospital, Neuss, Germany
    Anticancer Drugs 24:422-5. 2013
  3. pmc Coating with autologous plasma improves biocompatibility of mesh grafts in vitro: development stage of a surgical innovation
    Holger Gerullis
    Department of Urology, Lukas Hospital, Preußenstraße 84, 41464 Neuss, Germany West German Cancer Center WTZ, University of Essen, Essen, Germany German Centre for Assessment and Evaluation of Innovative Techniques in Medicine DZITM, Germany
    Biomed Res Int 2013:536814. 2013
  4. pmc Inflammatory reaction as determinant of foreign body reaction is an early and susceptible event after mesh implantation
    Holger Gerullis
    Department of Urology, Lukas Hospital, Preussenstraße 84, 41464 Neuss, Germany German Centre for Assessment and Evaluation of Innovative Techniques in Medicine DZITM, Germany
    Biomed Res Int 2014:510807. 2014
  5. doi Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma
    Holger Gerullis
    Department of Urology, Lukas Hospital, Neuss, Germany
    Med Oncol 27:373-8. 2010
  6. doi Early endoscopic detection and subsequent removal of sphincter penetrating anastomotic sutures may prevent irreversible urinary incontinence after radical prostatectomy
    Holger Gerullis
    Department of Urology, Lukas Hospital, Neuss, Germany
    J Endourol 26:889-94. 2012
  7. doi Sphincter lesions after radical prostatectomy-evaluation and classification
    Holger Gerullis
    Department of Urology, Lukas Hospital, Neuss, Germany
    J Endourol 25:1075-80. 2011
  8. doi Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma: a review
    Holger Gerullis
    Department of Urology, Lukas Hospital, Preussen Strasse 84, Neuss, Germany
    Anticancer Drugs 22:9-17. 2011
  9. doi Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany
    Holger Gerullis
    Department of Urology, Lukas Hospital, Neuss, Germany
    Cancer Chemother Pharmacol 63:1097-102. 2009
  10. doi IDEAL in meshes for prolapse, urinary incontinence, and hernia repair
    Holger Gerullis
    1Lukas Hospital, Neuss, Germany
    Surg Innov 20:502-8. 2013

Collaborators

  • Bernd Klosterhalfen
  • Thorsten H Ecke
  • Lothar Bergmann
  • Holger Gerullis
  • Thomas Otto
  • Evangelos Georgas
  • Mihaly Boros
  • Christian Arndt
  • Dimitri Barski
  • Bernhard Lammers
  • Sonja Quast
  • Jens W Bagner
  • Luise Maute
  • Dirk Ysebaert
  • Albert Ramon
  • Stephan Otto
  • Evagelos Georgas
  • Herbert Rubben
  • Melek Altindag
  • Melanie Homburger
  • Daria Orzechowski
  • Mohamed Wishahi
  • Jens Willem Bagner
  • Sunil Kocheril
  • Christoph J Heuck
  • Klaus Schwartmann

Detail Information

Publications11

  1. doi mTOR inhibition in advanced renal cell carcinoma: which criteria should be used to evaluate therapeutic outcome?
    Christoph Eimer
    Department of Urology, Lukas Hospital, Preussen Strasse 84, Neuss, Germany
    Anticancer Drugs 22:18-23. 2011
    ..It emphasizes the importance of adequate evaluation criteria for survival and QoL, as achieved by quality adjusted-time without symptoms and toxicity, in the palliative setting of advanced RCC...
  2. doi Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy
    Holger Gerullis
    Department of Urology, Lukas Hospital, Neuss, Germany
    Anticancer Drugs 24:422-5. 2013
    ..This phase I study showed that combined therapy of daily pazopanib (200 mg) and vinflunine (280/320 mg/m) every 3 weeks is poorly tolerated in patients with refractory advanced urothelial cancer...
  3. pmc Coating with autologous plasma improves biocompatibility of mesh grafts in vitro: development stage of a surgical innovation
    Holger Gerullis
    Department of Urology, Lukas Hospital, Preußenstraße 84, 41464 Neuss, Germany West German Cancer Center WTZ, University of Essen, Essen, Germany German Centre for Assessment and Evaluation of Innovative Techniques in Medicine DZITM, Germany
    Biomed Res Int 2013:536814. 2013
    ..To investigate mesh coating modalities with autologous blood components in a recently developed in vitro test system for biocompatibility assessment of alloplastic materials...
  4. pmc Inflammatory reaction as determinant of foreign body reaction is an early and susceptible event after mesh implantation
    Holger Gerullis
    Department of Urology, Lukas Hospital, Preussenstraße 84, 41464 Neuss, Germany German Centre for Assessment and Evaluation of Innovative Techniques in Medicine DZITM, Germany
    Biomed Res Int 2014:510807. 2014
    ..To investigate and relate the ultrashort-term and long-term courses of determinants for foreign body reaction as biocompatibility predictors for meshes in an animal model...
  5. doi Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma
    Holger Gerullis
    Department of Urology, Lukas Hospital, Neuss, Germany
    Med Oncol 27:373-8. 2010
    ..Further evaluation is necessary to define the oncological validity of this sequencing approach...
  6. doi Early endoscopic detection and subsequent removal of sphincter penetrating anastomotic sutures may prevent irreversible urinary incontinence after radical prostatectomy
    Holger Gerullis
    Department of Urology, Lukas Hospital, Neuss, Germany
    J Endourol 26:889-94. 2012
    ..The aim of this study was to identify early possible sphincter injuries as causes for urinary incontinence after radical prostatectomy by endoscopic evaluation of the anastomotic region...
  7. doi Sphincter lesions after radical prostatectomy-evaluation and classification
    Holger Gerullis
    Department of Urology, Lukas Hospital, Neuss, Germany
    J Endourol 25:1075-80. 2011
    ..The aim of this study was to analyze the sphincteric/perisphincteric lesions and modifications in incontinent patients with iatrogenic damage to the external urethral sphincter after radical prostatectomy (RP)...
  8. doi Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma: a review
    Holger Gerullis
    Department of Urology, Lukas Hospital, Preussen Strasse 84, Neuss, Germany
    Anticancer Drugs 22:9-17. 2011
    ....
  9. doi Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany
    Holger Gerullis
    Department of Urology, Lukas Hospital, Neuss, Germany
    Cancer Chemother Pharmacol 63:1097-102. 2009
    ..To detail tolerance of temsirolimus in a routine practice setting within a compassionate use program for patients with renal cell carcinoma...
  10. doi IDEAL in meshes for prolapse, urinary incontinence, and hernia repair
    Holger Gerullis
    1Lukas Hospital, Neuss, Germany
    Surg Innov 20:502-8. 2013
    ..Despite global spread of mesh applying surgeries, there is no current systematic analysis of incidence and possible prevention of adverse events after mesh implantation...
  11. doi Nephrocutaneous bypass in ureteral obstruction
    Holger Gerullis
    Department of Urology, Lukas Hospital, Neuss, Germany
    Urology 76:480-5. 2010
    ....